alemtuzumab

Phase 1/2Terminated

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Non-Hodgkins Lymphoma

Conditions

Non-Hodgkins Lymphoma

Trial Timeline

Dec 1, 2002 → Aug 1, 2005

NCT ID

NCT00051701

About alemtuzumab

alemtuzumab is a phase 1/2 stage product being developed by Sanofi for Non-Hodgkins Lymphoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT00051701. Target conditions include Non-Hodgkins Lymphoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (12)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03135249	Approved	Completed	May 1, 2018	Nov 4, 2020	Multiple Sclerosis (MS)
NCT03806387	Pre-clinical	Completed	Mar 1, 2017	Jun 30, 2021	Multiple Sclerosis
NCT03193086	Pre-clinical	UNKNOWN	Jan 1, 2017	Mar 31, 2020	Multiple Sclerosis
NCT02419378	Approved	Completed	Jun 1, 2015	Nov 1, 2020	Multiple Sclerosis, Relapsing-Remitting
NCT01395316	Approved	Completed	Jun 1, 2011	Jul 1, 2017	Multiple Sclerosis
NCT01333358	Phase 3	UNKNOWN	May 1, 2011	Mar 1, 2014	Multiple Sclerosis
NCT00923182	Phase 1	Completed	Feb 1, 2010	Aug 1, 2011	Leukemia, Lymphocytic, Chronic, B-Cell
NCT00930553	Phase 3	Completed	Aug 1, 2009	Feb 1, 2016	Multiple Sclerosis, Relapsing-Remitting
NCT00051701	Phase 1/2	Terminated	Dec 1, 2002	Aug 1, 2005	Non-Hodgkins Lymphoma
NCT00046683	Phase 3	Completed	Jul 1, 2001	Jun 1, 2006	B Cell Chronic Lymphocytic Leukemia
NCT00057967	Phase 2	Completed	Jul 1, 2000	Jul 26, 2010	Lymphoma
NCT00021151	Pre-clinical	Completed	Jan 1, 2000	May 1, 2002	Leukemia

Competing Products

15 competing products in Non-Hodgkins Lymphoma

See all competitors

Product	Company	Stage	Hype Score
Acalabrutinib + ACP-319	AstraZeneca	Phase 1/2	41
JBH492	Novartis	Phase 1	33
Glofitamab + Atezolizumab + Obinutuzumab + Tocilizumab + Polatuzumab Vedotin + 89Zr-Df-IAB22M2C	Roche	Phase 1/2	41
Obinutuzumab + Glofitamab + Gemcitabine + Oxaliplatin	Roche	Phase 2	52
Cyclophosphamide + Mitoxantrone + Vincristine + Prednisone + Rituximab	Amgen	Phase 2	51
hLL2 (epratuzumab)	Gilead Sciences	Phase 1	32
Velcade + Temsirolimus	Pfizer	Phase 2	51
Odronextamab + REGN5837	Regeneron Pharmaceuticals	Phase 1	32
Rituximab + 90Y ibritumomab tiuxetan (Zevalin) + Cyclophosphamide + Fludarabine	Bayer	Phase 1/2	38
Rituximab + Fludarabine + CAMPTH-1H	Bayer	Phase 2	49
Rituximab + CHOP + CVP + Ibritumomab Tiuxetan	Biogen	Phase 2	49
Ifosfamide + Carboplatin + Etoposide + Rituximab + 90Y Zevalin	Biogen	Phase 2	49
Ublituximab	TG Therapeutics	Phase 1/2	38
Ublituximab + Lenalidomide	TG Therapeutics	Phase 1	30
XmAb13676	Xencor	Phase 1	28

Other Products from Sanofi

Adacel®Approved

LACTIC ACID(ND)Approved

DupilumabApproved

glatiramer acetateApproved

INSULIN GLULISINE + INSULIN GLARGINEApproved